Bimagrumab Clinical Trials (2026): 11 Studies for Obesity & Sarcopenia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Bimagrumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Obesity & Sarcopenia) and 2,047 total planned enrollment. 1 Phase 3 Bimagrumab trial and 7 Phase 2 are listed. 1 Bimagrumab clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT05933499 (Mar 2029).
Where to Participate: All Bimagrumab Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting Bimagrumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| MA | Massachusetts General Hospital | Boston02114 | NCT05933499 | Map |
Bimagrumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | |||
| P2 | 1 | 1 | 4 | 1 | 7 |
| P2/P3 | 2 | 2 | |||
| P3 | 1 | 1 |
Recruiting Bimagrumab clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05933499 | Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity | P2 | Obesity | 63 | Nov 2025 |
Bimagrumab clinical trials by indication
Obesity (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05933499 | — | P2 | recruiting | Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity |
| NCT06643728 | LY3985863 | P2 | active not recruiting | A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight |
| NCT05616013 | — | P2 | completed | Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese |
| NCT06901349 | LY3985863 | P2 | withdrawn | A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes |
Sporadic Inclusion Body Myositis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02573467 | — | P3 | completed | An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 |
| NCT01925209 | RESILIENT | P2/P3 | completed | Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients |
Sarcopenia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02468674 | — | P2 | completed | A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study |
| NCT02333331 | — | P2 | completed | Dose Range Finding Study of Bimagrumab in Sarcopenia |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06890611 | LY3985863 | P1 | completed | A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants |
Muscle Wasting (Atrophy) After Hip Fracture Surgery (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02152761 | — | P2 | completed | Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery |
Sporadic Inclusion Body Myositis (sIBM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02250443 | BYM338 | P2/P3 | completed | Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis |
Bimagrumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| LY3985863 | NCT06643728 | P2 | active not recruiting | Obesity | 252 | — |
| LY3985863 | NCT06901349 | P2 | withdrawn | Obesity | 0 | — |
Terminated and withdrawn Bimagrumab trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06901349withdrawnA Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
All Bimagrumab trials (11)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05933499 | Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity | P2 | recruiting | 63 | Massachusetts General Hospital | Nov 2025 | |
| NCT06643728 | LY3985863 | A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight | P2 | active not recruiting | 252 | Eli Lilly and Company | Oct 2024 |
| NCT06890611 | LY3985863 | A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants | P1 | completed | 125 | Eli Lilly and Company | Mar 2025 |
| NCT05616013 | Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | P2 | completed | 507 | Eli Lilly and Company | Nov 2022 | |
| NCT06901349 | LY3985863 | A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes | P2 | withdrawn | 0 | Eli Lilly and Company | May 2025 |
| NCT02468674 | A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study | P2 | completed | 160 | Novartis Pharmaceuticals | Jul 2015 | |
| NCT02152761 | Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery | P2 | completed | 251 | Novartis Pharmaceuticals | Sep 2014 | |
| NCT02333331 | Dose Range Finding Study of Bimagrumab in Sarcopenia | P2 | completed | 217 | Novartis Pharmaceuticals | Dec 2014 | |
| NCT02573467 | An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 | P3 | completed | 211 | Novartis Pharmaceuticals | Nov 2015 | |
| NCT02250443 | BYM338 | Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis | P2/P3 | completed | 10 | Novartis Pharmaceuticals | Mar 2014 |
| NCT01925209 | RESILIENT | Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients | P2/P3 | completed | 251 | Novartis Pharmaceuticals | Sep 2013 |
Bimagrumab clinical trials: frequently asked questions
- How many Bimagrumab clinical trials are there?
- 11 Bimagrumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 8 are marked completed.
- Are Bimagrumab clinical trials recruiting in 2026?
- Yes — 1 Bimagrumab trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is Bimagrumab being studied for?
- Bimagrumab is being studied for Obesity, Sarcopenia, Sporadic Inclusion Body Myositis, Overweight, Healthy and 4 more. The trials are grouped by indication on this page.
- What phase is Bimagrumab in?
- Bimagrumab clinical trials span 1 Phase 3, 7 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Bimagrumab clinical trials?
- The lead sponsor across the most Bimagrumab trials is Novartis Pharmaceuticals, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Bimagrumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: